Recursion Pharmaceuticals, Inc. (RXRX)

NASDAQ: RXRX · Real-Time Price · USD

3.700

-0.350 (-8.64%)

At close: Sep 23, 2026, 4:00 PM EDT

3.700

0.00 (0.00%)

After-hours: Sep 23, 2026, 4:55 PM EDT

Recursion Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	54.86	74.68	58.84	44.58	39.84	10.18
Revenue Growth	-15.08%	26.92%	32.00%	11.88%	291.46%	156.89%
Cost of Revenue	447.46	546.22	359.66	283.81	203.97	135.27
Gross Profit	-392.6	-471.54	-300.82	-239.24	-164.13	-125.09
Selling, General & Admin	157.37	176.59	178.18	110.82	81.6	57.68
Operating Expenses	157.37	176.59	178.18	110.82	81.6	57.68
Operating Income	-549.97	-648.13	-479	-350.06	-245.73	-182.78
Interest Expense	-1.48	-1.81	-1.57	-0.1	-0.06	-2.95
Interest & Investment Income	23.06	22.79	15.76	19.12	6.25	0.07
Other Non Operating Income (Expenses)	-1.03	-17.74	0.03	-1.09	0.05	0
EBT Excluding Unusual Items	-529.42	-644.9	-464.79	-332.13	-239.48	-185.65
Other Unusual Items	-	-	-	-	-	-0.83
Pretax Income	-523.47	-644.9	-464.79	-332.13	-239.48	-186.48
Income Tax Expense	-4.58	-0.14	-1.13	-4.06	-	-
Net Income	-518.88	-644.76	-463.66	-328.07	-239.48	-186.48
Net Income to Common	-518.88	-644.76	-463.66	-328.07	-239.48	-186.48
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	508	447	274	208	176	125
Shares Outstanding (Diluted)	508	447	274	208	176	125
Shares Change	41.13%	63.18%	31.92%	18.41%	40.04%	475.48%
EPS (Basic)	-1.02	-1.44	-1.69	-1.58	-1.36	-1.49
EPS (Diluted)	-1.02	-1.44	-1.69	-1.58	-1.36	-1.49
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-352.27	-378.28	-372.87	-299.74	-120.58	-198.41
Free Cash Flow Per Share	-0.69	-0.84	-1.36	-1.44	-0.69	-1.58
Operating Margin	-1002.56%	-867.87%	-814.09%	-785.33%	-616.74%	-1795.79%
Profit Margin	-945.90%	-863.35%	-788.02%	-735.99%	-601.05%	-1832.18%
Free Cash Flow Margin	-642.17%	-506.52%	-633.71%	-672.43%	-302.64%	-1949.42%
EBITDA	-471.6	-564.43	-442.51	-325.66	-233.97	-174.37
D&A For EBITDA	78.36	83.7	36.49	24.4	11.76	8.41
EBIT	-549.97	-648.13	-479	-350.06	-245.73	-182.78
Revenue as Reported	54.86	74.68	58.84	44.58	39.84	10.18

SEC Filings: 10-K · 10-Q